The Biden administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use march-in rights.

The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.

The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.

“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.

  • lobut@lemmy.ca
    34·
    1 year ago

    It really annoys me when they Biden has done nothing.

    Then they’re all, “well I didn’t hear about it”

    I get that the media and even the Dems suck at showing people what they’ve accomplished, but that doesn’t mean they’ve done nothing.

    • Random Dent@lemmy.ml
      20·
      1 year ago

      It’s that usual right-wing thing, where their opponent is simultaneously an idiot who does nothing, and also a scheming mastermind who’s responsible for all the trouble in the world depending on which way the wind’s blowing.